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Adjuvant Migraine Medications in the Treatment of Sudden
Sensorineural Hearing Loss
Mehdi Abouzari, MD, PhD† ; Khodayar Goshtasbi, BS†; Janice T. Chua, BS† ; Donald Tan, BA;
Brooke Sarna, BS; Tina Saber, MD; Harrison W. Lin, MD; Hamid R. Djalilian, MD
Objectives/Hypothesis: To examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL)
treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was
that adjuvant migraine medications may improve outcomes in SSNHL.
Methods: A retrospective chart review at a tertiary otology center was conducted to identify patients with SSNHL who received
oral steroid and IT dexamethasone injection(s) with or without migraine medications (a combination of nortriptyline and topiramate).
Results: A total of 47 patients received oral steroid and IT dexamethasone injection(s) only, and 46 patients received oral
steroid and IT dexamethasone injection(s) as well as migraine lifestyle changes plus a combination of nortriptyline and
topiramate. There were no significant differences in demographics and baseline audiometric data between the two groups.
Both groups demonstrated improvements in pure tone average (PTA) and hearing thresholds at 250 Hz and 8000 Hz post-
treatment. However, compared to steroid-only group, the adjuvant migraine medications group had significantly greater
improvements in hearing thresholds at the lower frequencies (250 Hz, 500 Hz, 1000 Hz). Patients in the latter cohort also had
greater improvement in PTA (P = .01) and received fewer IT injections (P = .04) PTA improvement of ≥ 10 dB was observed in
36 patients (78%) in the adjuvant migraine medications group and 22 patients (46%) in the control group (P < .001).
Conclusion: In multimodal treatment of SSNHL, supplementing oral and IT steroid with migraine medications may result
in greater improvements in lower frequency hearing thresholds and PTA. Furthermore, adjuvant migraine treatment can lead
to decrease in number of IT injections, thus reducing procedure-related risks and complications.
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INTRODUCTION
Sudden sensorineural hearing loss (SSNHL) can be
defined as a rapid onset >30 dB reduction in sensorineu-
ral thresholds of three contiguous audiometry frequencies
within 3 days. With a current estimated incidence of
27 per 100 thousand U.S. adults, SSNHL is associated
with male gender and older age.1 It most commonly pre-
sents as a unilateral hearing loss upon waking up, and
concurrent or subsequent bilateral involvement is not fre-
quent.2,3 The pathophysiology and management of this
entity has remained a subject of debate. SSNHL can arise
from known etiopathologies (29%) such as infections,
otologic diseases, trauma, hematologic or vascular disor-
ders, and tumors, whereas most cases (71%) may be reg-
arded as idiopathic.3 It has been suggested that age and
time to treatment, as well as vertigo, profound or contra-
lateral hearing impairment, and audiogram shape, can be
associated with prognosis.4–6 Even though up to one-third
to two-thirds of patients may spontaneously recover,7,8
intratympanic (IT) and systemic steroid administration
are among the widely utilized treatment options.8–10
Despite this, in a 2014 meta-analysis of randomized
controlled trials comparing steroid and placebo treat-
ments for SSNHL, Crane et al. demonstrated no signifi-
cant difference except in the case of salvage treatment.11
This has called for further investigation into discovering
new and improved management solutions for better
treating SSNHL. One of the theoretical etiologies of idio-
pathic SSNHL has been attributed to vascular impair-
ment to the cochlea.12,13 This may align with evidence
suggesting a possible association between cardiovascular
risk factors and SSNHL occurrence.3,14,15 There have also
been nationwide population-based and prospective cohort
studies suggesting that migraine, a complex neuro-
vascular disorder, can increase the risk for developing
SSNHL.16–18 Thus, we present an investigation to evalu-
ate the efficacy of supplementing IT steroid injection with
migraine medications in improving SSNHL treatment
outcome.
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MATERIALS AND METHODS
In this cohort study, we describe the treatment of patients
with SSNHL who presented to our tertiary care neurotology
practice from January 2014 to March 2019. These patients were
treated with either standard care or standard care plus adjuvant
multimodal migraine prophylactic regimen. Standard care for all
patients was prednisone 1 mg/kg (up to 80 mg) daily for 7 days
and a 6-day taper. In addition, all patients were injected with
dexamethasone 10 mg/mL intratympanically at least twice, on a
frequency of 2 times a week. If the patient had improvement, fur-
ther injections were performed twice a week until no audiometric
improvement was seen from one visit to the next. Approval was
obtained from the institutional review board of the University of
California, Irvine, California. Patients with sudden onset of hear-
ing loss were evaluated using the U.S. National Institute for
Deafness and Communication Disorders (NIDCD) definition for
SSNHL, which is “an idiopathic loss of hearing of at least 30 dB
over at least three contiguous test frequencies occurring within
3 days.”19(p2) All included patients had presented within 10 days
of hearing loss onset, and time to presentation was consistent
across the entire cohort. The standard workup for patients
included measurement of baseline pure-tone audiometry and
speech recognition threshold (SRT), word discrimination tested
at a level of 40 dB above SRT, as well as magnetic resonance
imaging of the internal auditory canal to rule out other causes.
Pure tone average (PTA) was measured in accordance with the
Committee on Hearing and Equilibrium Guidelines, utilizing
thresholds at frequencies of 500 Hz, 1000 Hz, 2000 Hz, and
4000 Hz.20 Moreover, word recognition score (WRS) was obtained
per American Academy of Otolaryngology–Head and Neck Sur-
gery standardized format for reporting hearing outcome.21
In total, 93 patients were treated for SSNHL and included
in this study. These patients were assigned retrospectively to the
control group (standard care) or the adjuvant migraine medica-
tions group (standard care plus adjuvant therapy). Starting in
April 2015, patients were additionally offered a regimen of adju-
vant migraine prophylactic medication at the initial visit. As such,
patients treated prior or following this date were assigned to the
control or adjuvant migraine medications groups, respectively,
with the exception of post-April 2015 patients in whom migraine
medications were contraindicated (N = 3) and were analyzed as
part of the control cohort. All patients were evaluated for whether
they met the International Classification of Headache Disorders
(ICHD) 3rd edition beta criteria for migraine with or without aura
(Table I)22 through the administration of a comprehensive ques-
tionnaire given to all patients presenting to our neurotology clinic.
Patients who were already receiving migraine medications for a
previous migraine diagnosis were excluded.
As part of the migraine prophylaxis, patients were
counseled on implementing migraine lifestyle modifications. This
included dietary modifications, which consisted of avoiding foods
containing certain preservatives, fermented products, chocolate,
nuts, eggs, alcohol, fresh breads/yeast products, aged/processed
meats, certain beans, certain fruit (high histamine), and pickled
or preserved fruits/vegetables.23 In addition, dietary supplemen-
tation with magnesium 400 mg orally twice a day and riboflavin
(vitamin B2) 200 mg orally twice a day was prescribed. We did
not restrict sodium intake as long as the patient stayed well-
hydrated. Patients were also instructed to eat three meals and
sleep on a regular schedule to avoid fatigue, hunger, and dehy-
dration. The patients were also prescribed pharmacologic
migraine prophylaxis with nortriptyline 25 mg orally before bed-
time and gradually escalated by 25 mg every 2 weeks to a maxi-
mum dose of 75 mg. In addition, topiramate 25 mg orally before
bedtime with weekly escalation of 25 mg up to 150 mg was pre-
scribed. Medication adherence was emphasized on every follow-
up visit, and a lack of compliance led to exclusion from the study.
Patients were re-evaluated twice a week with an audio-
gram. After the two IT steroid injections, the decision was made
whether to continue with IT dexamethasone injection: if there
was improvement in hearing. In some patients, the dose escala-
tion was performed faster initially with increase in the
topiramate dose every 3 to 4 days and nortriptyline at 7 to
10 days post-onset of treatment. Thus, the treatment duration in
some patients was shorter and approximately 4 weeks, whereas
some patients were treated for the full 6 weeks when escalations
were performed as initially planned. Patients who received
migraine prophylactic medications were eventually tapered after
4 to 6 weeks when maximum dose was achieved. Posttreatment
audiometry was defined as the audiometric results obtained at
the final visit. Paired samples t test was performed to compare
pre- and posttreatment audiometric measurements. Further-
more, chi-square and independent sample t test were used to
compare categorical and numerical variables between the two
groups, respectively. SPSS 17.0 software (SPSS Inc., Chicago, IL)
was used for statistical analysis with a 0.05 alpha considered
significant.
RESULTS
Of the 93 patients included in this study, 47 were
assigned to the control group (received oral and IT steroids)
and 46 to the adjuvant migraine medications group
(in addition to oral and IT steroids). As shown in Table II,
therewere no significant differences in age, sex, baseline PTA,
baseline WRS, or migraine history between the two groups.
There were no tympanic membrane (TM) complications on
otomicroscopy plus tympanometry associated with IT injec-
tions, including permanent perforation, in either cohort.
There were no reported adverse events associated with the
TABLE I.
Diagnostic Criteria of Migraine With or Without Aura According to
ICDH 3rd Edition Beta Criteria.
Diagnostic criteria of migraine without aura:
A. At least five attacks fulfilling criteria B–D
B. Headache attacks lasting 4–72 hrs (untreated or unsuccessfully treated)
C. Headache has at least two of the following four characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical activity
(e.g., walking or climbing stairs)
D. During headache at least one of the following:
1. Nausea and/or vomiting
2. Photophobia and phonophobia
E. Not better accounted for by another ICHD-3 diagnosis.
Diagnostic criteria of migraine with aura:
A. At least two attacks fulfilling criteria B and C
B. One or more of the following fully reversible aura symptoms:
1. Visual
2. Sensory
3. Speech and/or language
4. Motor
5. Brainstem
6. Retinal
C. At least two of the following four characteristics:
1. At least one aura symptom spreads gradually over ≥ 5 min, and/or two
or more symptoms occur in succession
2. Each individual aura symptom last 5–60 min
3. At least one aura symptom is unilateral
4. The aura is accompanied, or followed within 60 min, by headache
D. Not better accounted for by another ICHD-3 diagnosis, and transient
ischemic attack has been excluded.
Hrs = hours; ICDH = International Classification of Headache Disor-
ders, 3rd edition; min = minutes.
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administration of migraine medications. Complaints of dry
mouth and somnolence occurred when the medications were
escalated to the higher dosages; however, none of the side
effects led to noncompliance.
The adjuvant migraine medications group had a
lower average SRT, although this difference did not reach
statistical significance (62  25 dB vs. 53  26 dB,
P = .10). The control group had a higher average number
of IT dexamethasone injections, which met significance
(3.1  2.0 vs. 2.4  1.1, P = .04). As shown in Table III,
both groups demonstrated a significant improvement in
hearing thresholds in both high and low frequencies at
the 4 to 6 week follow-up. The control group pretreatment
PTA was 73  26 dB versus 61  28 dB posttreatment,
P < .001. The adjuvant migraine medication group
improved from 74  22 dB pretreatment to 55  22 dB
posttreatment, P < .001. Whereas both groups showed
improvement in average SRT, only the control group met
statistical significance (P = .004). Moreover, both groups
experienced significant improvement in WRS outcomes:
from 29  34% pretreatment to 53  40% posttreatment
in the control group (P < .001), and from 23  34% pre-
treatment to 56  38% posttreatment in adjuvant
migraine medications group (P < .001).
The comparison of calculated differences in pre- and
posttreatment hearing thresholds at different frequen-
cies, PTA, SRT, and WRS between the two groups are
shown in Table IV. The adjuvant migraine medications
group showed a significantly greater improvement in
hearing compared to the control group, as measured by
change in PTA (P = .01). Specifically, the greater improve-
ments on hearing thresholds were statistically significant
in the contiguous lower frequencies of 250 Hz, 500 Hz,
and 1000 Hz (P = .02, P = .01, and P = .001; respectively).
PTA improvement of ≥ 10 dB was observed in 36 patients
(78%) in the adjuvant migraine medications group and
22 patients (46%) in the control group (P < .001), whereas
PTA improvement of ≥ 20 dB was observed in 28 patients
(61%) in the adjuvant migraine medications group and
12 patients (25%) in the control group (P < .001).
DISCUSSION
This retrospective study of SSNHL patients demon-
strated that supplementing oral steroid and IT dexameth-
asone injections with migraine medications led to greater
hearing improvement in lower frequency thresholds and
PTA as well as a need for fewer IT injections. Although
both “oral and IT steroid with migraine treatment” and
“oral and IT steroid only” groups experienced symptom-
atic improvements, the statistically significant greater
improvement of the adjuvant migraine medications
cohort (Fig. 1), despite a similar prevalence of migraine
history, may shed light on a similar underlying vascular
etiology among both migraine and idiopathic SSNHL. If
TABLE II.
The Cohort Demographics, Baseline Audiometry, and Total
Intratympanic Steroid Injections.
Control Group
Adjuvant Migraine
Medications Group P value
Age 56.8  17.4 60.2  14.3 .30
Sex (M:F) 27:20 27:19 1.00
Migraine history 20 (42%) 17 (37%) .58
PTA (dB) 73  26 74  22 .80
SRT (dB) 62  25 53  26 .10
WRS (%) 29  34 23  34 .37
No. of IT injections 3.1  2.0 2.4  1.1 .04*
Asterisk denotes statistically significant P value.
F = female; IT = intratympanic; M = male; PTA = pure tone average;
SRT = speech recognition threshold; WRS = word recognition score.
TABLE III.
Comparison of Pre- and Posttreatment Audiometry Between the
Two Groups.
Pretreatment
Hearing
Threshold/Score
Posttreatment
Hearing
Threshold/Score P Value
Control group
250 Hz (dB) 68  25 57  29 < .001*
8000 Hz (dB) 75  20 68  24 < .001*
PTA (dB) 73  26 61  28 < .001*
SRT (dB) 62  25 51  31 .004*
WRS (%) 29  34 53  40 < .001*
Adjuvant migraine medications group
250 Hz (dB) 63  27 42  20 < .001*
8000 Hz (dB) 74  28 64  29 < .001*
PTA (dB) 74  22 55  22 < .001*
SRT (dB) 53  26 45  23 .11
WRS (%) 23  34 56  38 < .001*
Asterisk denotes statistically significant P value.
PTA = pure tone average; SRT = speech recognition threshold;
WRS = word recognition score.
TABLE IV.
Comparison of Calculated Differences in Pre- and Posttreatment
Hearing Thresholds at Different Frequencies, PTA, SRT, and WRS
Between the Two Groups.
Improvement in Threshold (Δ dB) or Score (Δ%)
Control
Group
Adjuvant Migraine
Medications Group P Value
250 Hz (dB) 11  16 21  22 .02*
500 Hz (dB) 14  15 24  20 .01*
1000 Hz (dB) 13  17 25  16 .001*
2000 Hz (dB) 11  14 16  13 .09
4000 Hz (dB) 9  13 10  12 .78
8000 Hz (dB) 7  12 10  13 .14
PTA (dB) 12  13 19  13 .01*
SRT (dB) 11  20 7  30 .54
WRS (%) 23  30 33  33 .14
Asterisk denotes statistically significant P value.
PTA = pure tone average; SRT = speech recognition threshold;
WRS = word recognition score.
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true, this can result in further investigative pursuit of
potentially novel treatment strategies for SSNHL.
Among various causes of hearing loss, idiopathic
SSNHL has attracted disproportionate research interest.
This is likely due to its potentially reversible natural course
as well as its emergent treatment window, rendering all
otolaryngologists as key clinicians for care of these
patients.24 With no current consensus on a treatment regi-
men, otolaryngologists may use one or a combination of
options, such as systemic steroid, IT steroid, antiviral or
anticoagulating agents, hyperbaric oxygen, antioxidants,
and vasodilators. It is suggested that older age and delayed
time to treatment, as well as associated vertigo, hyperten-
sion, and diabetes, can be associated with lower recovery
rates.4,5 There is abundant evidence supporting the efficacy
of IT steroid therapy for SSNHL hearing improvement,
especially if refractory to systemic medication or for salvage
treatment.24–30 In accordance with the literature, our con-
trol group experienced symptomatic improvements with
oral and IT steroid injections. However, this manuscript is
the first to report additional SSNHL outcome improve-
ments with supplementing migraine medications such as
nortriptyline and topiramate.
The similar prevalence of migraine history between
the two cohorts further suggests that the prophylactic regi-
men may independently provide therapeutic benefit
regardless of a history of classical migraine. Similar bene-
fits from migraine prophylactic regimen have also been
demonstrated in other complex otologic disorders such as
hyperacusis, vertigo, and Meniere disease.31–33 This may
be due to similar underlying vascular pathophysiology
between SSNHL andmigraine, which is in line with Dogan
et al.’s finding that prophylactic migraine treatment such
as topiramate may reduce endothelial pulse wave velocity
and also lead to decreased long-term cardiovascular
risks.34 Topiramate’s positive role in regulating cerebro-
vascular autonomic control has also been speculated.35
The potential neuroprotective effects of nortriptyline
against cerebral ischemia further support these prophylac-
tic medications’ vascular effects,36 which could explain its
observed benefits to patients with migraine as well as
SSNHL. Verapamil, which is another drug commonly used
for treating migraine, is also associated with significantly
decreased cerebrovascular resistance.37–39 The aforemen-
tioned studies, among others, suggest that migraine pro-
phylactic medications may provide therapeutic benefit to
both migraine and SSNHL by altering vascular flow and
addressing a potentially similar underlying
pathophysiology.
In this investigation, we demonstrated that
supplementing oral and IT steroidswithmigrainemedications
led to significantly improved recovery of low frequency
(250, 500, and 1000 Hz) hearing loss. Furthermore, there was
both a greater improved PTA as well as a lesser frequency of
required IT injections in the combination-treated cohort. The
decreased number of required injections were likely due to
patients’ earlier hearing recovery back to normal compared to
those who did not receive adjuvant migraine treatment.
Because migraine is a complex neurovascular disorder, this
can imply that SSNHL may have an underlying vascular or
neurogenic inflammatory pathophysiology similar to
migraine, which can explain the improved outcomes observed
in this experiment. Oh et al.’s recent report of a unique gene
associated with progressive SNHL associated with migraine
may be one route to examine this close relationship.40 It is
already well established that migraine and vestibular symp-
toms can have a close relationship and association in the diag-
nosis of vestibular migraine.41–43 Similarly, there has been
continuous speculation of whether migraine can damage the
inner ear in association with pathologies such as sudden hear-
ing loss and delayed endolymphatic hydrops.44 Investigation
of large nation-wide databases have further revealed that
migraine is a risk factor associated with developing
SSNHL.17,18 It is thusplausible to consider a theoretical vascu-
lar relationship between migraine and idiopathic SSNHL as
an explanation for our observed significantly improved hear-
ing recoverywith the supplementation ofmigraine treatment.
A prospective study by Arslan et al. reported that
although SSNHL patients had a higher prevalence of
migraine, the rates of SSNHL recovery between patients
with or without migraine were statistically similar.16 The
previously mentioned study by Chu et al. also observed
that migraine medications such as acetaminophen,
NSAIDs, and triptans were not risk factors for developing
SSNHL among migraine patients.17 It is reasonable to
argue that these findings support our interpretation that
the improved SSNHL recovery stemming from supple-
menting migraine medication may be applicable to all
SSNHL patients as opposed to only those with symptom-
atic migraine comorbidities.
Our lack of TM complications or permanent injury
with IT injection was consistent with reports in the litera-
ture describing its relative safety.45 However, because
multiple IT injections do add theoretical risk to TM injury
and may subsequently impact low-frequency PTA,46–48
the investigation of novel treatments that may decrease
the number of necessary IT injections, such as the
described migraine prophylactic medications, is impor-
tant. The lack of TM complications following IT injections
in our studied cohort can be attributed to: 1) application
of a very small amount of phenol (approximately the size
of a 25 Ga needle) on the TM to minimize the chance of
Fig. 1. Posttreatment improvement in hearing thresholds among the
two cohorts, demonstrating a significant improvement in the experi-
mental group (oral and intratympanic steroid with migraine treat-
ment; N = 46) compared to controls (oral and intratympanic steroid
only; N = 47) in the low frequencies. Error bars represent 1 stan-
dard error of means.
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perforation persistence, 2) performing subsequent injec-
tions in a different area of the TM to minimize trauma to
the same spot, and 3) patients were instructed on dry ear
precautions and no nose blowing to minimize the chance
of perforation persistence.
The selected dosages of nortriptyline and topiramate
have previously been shown to be both safe and effective
for treatment of other otologic conditions.31–33,49,50 How-
ever, it is worth noting that these migraine medications
have potential side effects that should be considered and
monitored. Nortriptyline can cause lightheadedness,
whereas topiramate can lead to mild disturbance in taste,
appetite, and paresthesia of distal extremities. Nortripty-
line can also cause sedation and disturbance in cardiac
rhythm, the latter of which can be monitored with electro-
cardiograms. The studied cohort did not experience any
major adverse events, which can be attributed to careful
dose escalation or de-escalation depending on symptom-
atic improvement and tolerance. We have noticed that the
patients with sudden hearing loss tend to be more compli-
ant with the migraine medication regimen compared to
our vestibular migraine patients. The nature of the deficit
with sudden hearing loss and the perceived long-term con-
sequences may play a role in improved compliance even in
the presence of side effects. Though we remain cautious
regarding potential risks associated with IT injection and
migraine prophylactic medications, it is important to bal-
ance these risks with potential reward of SSNHL
treatment.
It was observed that although there were no signifi-
cant differences between the two cohorts’ pretreatment
PTA and SRT, the adjuvant migraine group had a nonsig-
nificant larger difference between PTA and SRT compared
to the control group. In our clinical experience, we have
observed that the SRT in general tends to be sensitive to a
single threshold in a non-PTA frequency. For instance, if a
patient has a 25-dB threshold at 250 Hz or 3000 Hz, the
SRT tends to be significantly better than the PTA (if the
thresholds at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz are
lower than that single good frequency). Whereas the PTA-
SRT difference seemed different between the two cohorts, it
did not reach statistical significance, and thus the two
cohorts’ different levels of improvement from statistically
similar baselines can be attributed to their treatments. In
addition to observing greater improvements in low-
frequency hearing thresholds, it was demonstrated that a
significantly higher proportion of migraine-adjuvant
patients experienced improved PTA (which was derived
from 500, 1000, 2000, and 4000 Hz frequencies) compared
to controls. Namely, 78% and 46% of the adjuvant migraine
group experienced 10 dB and 20 dB improvements com-
pared to 46% and 25% in the control group, respectively,
demonstrating hearing improvement affecting a signifi-
cantly larger proportion of patients. Additionally, the mere
25% of control patients experiencing ≥ 10 dB improvement
is low, which leads us to consider further treatment that
can result in improved hearing and possibly translate to
better quality of life. Lastly, although WRS improvement
was not significantly different between the two groups, its
relatively larger change in the treatment cohort (33%
vs. 23%) may be nonsignificant due to the retrospective
nature of the current study and its limitations, which will
be discussed fur-
ther. Despite this, the aforementioned findings suggesting
favorable outcomes following adjuvant migraine medication
treatment warrant further investigations into its utility for
SSNHL. Future research is especially important because
many SSNHL patients may not receive any treatment
besides steroid therapy, even if it proves not efficacious.
Although great effort was taken to ensure the valid-
ity of this study from methodology and patient inclusion
to analysis, there exist some limitations. First, the retro-
spective chart-review nature of this study precludes con-
cluding that migraine medication is efficacious for all
SSNHL patients as opposed to a subset of patients with
certain characteristics or presentations. Future placebo-
controlled prospective cohort studies are warranted to
better characterize treatment outcomes of SSNHL follow-
ing standard care (oral and IT steroid) versus standard
care plus adjuvant migraine medications. As part of the
migraine prophylactic regimen, patients were thoroughly
counseled on the dietary and lifestyle modifications on
every clinic visit and were offered handouts with written
information. However, due to the multifactorial and
patient-specific nature of the dietary and lifestyle modifi-
cations, there may exist a sizable variety in patient com-
pliance that was not measured. Medication compliance
was also subjectively reported by patients on follow-up
visits, which can be improved upon via routine medica-
tion adherence self-reported questionnaires or medication
monitoring devices in future research.51,52 Lastly, SSNHL
is a relatively rare entity, further limiting the cohort sizes
for experimentation and statistical comparison. Despite
these limitations, this study may serve as an initiative to
further investigate the possible efficacy of migraine medi-
cations for an enhanced treatment of SSNHL in a ran-
domized clinical trial.
CONCLUSION
SSNHL patients who received adjuvant migraine
medications experienced greater improvement in lower
frequency hearing thresholds and PTA compared to
patients who only received standard oral and IT steroid
injections. Furthermore, the utilization of migraine medi-
cations in SSNHL treatment was also associated with
fewer IT injections, which can reduce risks of procedure-
related complications.
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